Aktieanalys

XVIVO: 12-month follow-up results from European multicenter heart trial - Redeye

{newsItem.title}

Redeye Publicerad: Igår 14:37

Xvivo Perfusion

The 12-month safety results confirm and extend the earlier results after 3 months, adding support both ahead of the European, Canadian and US launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1099772/xvivo-12-month-follow-up-results-from-european-multicenter-heart-trial?utm_source=finwire&utm_medium=RSS

Nyheter om Xvivo Perfusion

Läses av andra just nu

Om aktien Xvivo Perfusion

Senaste nytt